Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease

Blood

Volumn 124, Issue 24, 2014, Pages 3544-3552

  Uldrick, Thomas S ^a   Polizzotto, Mark N ^a   Aleman, Karen ^a   Wyvill, Kathleen M ^a   Marshall, Vickie ^b   Whitby, Denise ^b   Wang, Victoria ^a   Pittaluga, Stefania ^a   O'Mahony, Deirdre ^a   Steinberg, Seth M ^a   Little, Richard F ^a   Yarchoan, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; C REACTIVE PROTEIN; DOXORUBICIN; IMMUNOGLOBULIN LIGHT CHAIN; INTERLEUKIN 6; RITUXIMAB; VALGANCICLOVIR; ZIDOVUDINE; ANTINEOPLASTIC ANTIBIOTIC; ANTIRETROVIRUS AGENT; IL6 PROTEIN, HUMAN; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY;

ADULT; ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANOREXIA; ANTIVIRAL THERAPY; ARTICLE; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; EVENT FREE SURVIVAL; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOALBUMINEMIA; IMMUNOGLOBULIN BLOOD LEVEL; INFUSION RELATED REACTION; KAPOSI SARCOMA; KAPOSI SARCOMA HERPESVIRUS ASSOCIATED MULTICENTRIC CASTLEMAN DISEASE; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; STOMATITIS; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS LOAD; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; DISEASE FREE SURVIVAL; GIANT LYMPH NODE HYPERPLASIA; HERPESVIRIDAE INFECTIONS; HIV INFECTIONS; HUMAN HERPESVIRUS 8; METABOLISM; MIDDLE AGED; MORTALITY;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; C-REACTIVE PROTEIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; GIANT LYMPH NODE HYPERPLASIA; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RITUXIMAB; SURVIVAL RATE; VIRAL LOAD;

EID: 84915747028     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-586800     Document Type: Article

References (67)

1. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995;86(4):1276-1280.
2. Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood. 2011;117(26):6977-6986.
3. Polizzotto MN, Uldrick TS, Wang V, et al. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood. 2013;122(26):4189-4198.
4. Bower M. How I treat HIV-associated multicentric Castleman disease. Blood. 2010;116(22):4415-4421.
5. Bower M, Pria AD, Coyle C, Nelson M, Naresh K. Diagnostic criteria schemes for multicentric Castleman disease in 75 cases. J Acquir Immune Defic Syndr. 2014;65(2):e80-e82.
6. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10(1):61-67.
7. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood. 2000;96(6):2069-2073.
8. Bower M, Newsom-Davis T, Naresh K, et al. Clinical Features and Outcome in HIV-Associated Multicentric Castleman's Disease. J Clin Oncol. 2011;29(18):2481-2486.
9. Hoffmann C, Tabrizian S, Wolf E, et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS. 2001;15(16):2119-2127.
10. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266(5192):1865-1869.
11. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332(18):1186-1191.
12. Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood. 1996;88(2):645-656.
13. Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood. 2002;99(7):2331-2336.
14. Gérard L, Michot JM, Burcheri S, et al. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood. 2012;119(10):2228-2233.
15. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF. HIV-associated lymphomas and gamma-herpesviruses. Blood. 2009;113(6):1213-1224.
16. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95(4):1406-1412.
17. Uldrick TS, Wang V, O'Mahony D, et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis. 2010;51(3):350-358.
18. Fardet L, Blum L, Kerob D, et al. Human herpesvirus 8-associated hemophagocytic lymphohistiocytosis in human immunodeficiency virus-infected patients. Clin Infect Dis. 2003;37(2):285-291.
19. Stebbing J, Ngan S, Ibrahim H, et al. The successful treatment of haemophagocytic syndrome in patients with human immunodeficiency virus-associated multi-centric Castleman's disease. Clin Exp Immunol. 2008;154(3):399-405.
20. Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood. 2014;123(19):2924-2933.
21. Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013;19(13):3659-3670.
22. Markham A, Patel T. Siltuximab: first global approval. Drugs. 2014;74(10):1147-1152.
23. van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966-974.
24. Uldrick TS, Polizzotto MN, Yarchoan R. Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Curr Opin Oncol. 2012;24(5):495-505.
25. Bollen J, Polstra A, Van Der Kuyl A, et al. Multicentric Castleman's disease and Kaposi's sarcoma in a cyclosporin treated, HIV-1 negative patient: case report. BMC Blood Disord. 2003;3(1):3.
26. Nord JA, Karter D. Low dose interferon-alpha therapy for HIV-associated multicentric Castleman's disease. Int J STD AIDS. 2003;14(1):61-62.
27. Kumari P, Schechter GP, Saini N, Benator DA. Successful treatment of human immunodeficiency virus-related Castleman's disease with interferon-alpha. Clin Infect Dis. 2000;31(2):602-604.
28. Lee FC, Merchant SH. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. Am J Hematol. 2003;73(1):48-53.
29. Casper C, Nichols WG, Huang ML, Corey L, Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood. 2004;103(5):1632-1634.
30. Gill PS, Loureiro C, Bernstein-Singer M, Rarick MU, Sattler F, Levine AM. Clinical effect of glucocorticoids on Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1989;110(11):937-940.
31. Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A. Multicentric Castleman's disease in HIV infection: a systematic review of the literature. AIDS Rev. 2008;10(1):25-35.
32. Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcomaassociated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood. 2001;98(12):3473-3475.
33. Marcelin AG, Aaron L, Mateus C, et al. Rituximab therapy for HIV-associated Castleman disease. Blood. 2003;102(8):2786-2788.
34. Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol. 2007;25(22):3350-3356.
35. Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007;147(12):836-839.
36. Shortt J, Spencer A. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant. 2006;38(6):433-436.
37. Stebbing J, Gazzard B, Newsom-Davis T, et al. Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcoma. Int J Cancer. 2004;108(3):473-474.
38. Huang KH, Bonsall D, Katzourakis A, et al. B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nat Commun. 2010;1(7):102.
39. Kimball LE, Casper C, Koelle DM, Morrow R, Corey L, Vieira J. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. J Infect Dis. 2004;189(11):2016-2022.
40. Burbelo PD, Issa AT, Ching KH, et al. Distinct profiles of antibodies to Kaposi sarcomaassociated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma. J Infect Dis. 2010;201(12):1919-1922.
41. Neuville S, Agbalika F, Rabian C, Brière J, Molina JM. Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease. Am J Hematol. 2005;79(4):337-339.
42. Buchler T, Dubash S, Lee V, et al. Rituximab failure in fulminant multicentric HIV/human herpesvirus 8-associated Castleman's disease with multiorgan failure: report of two cases. AIDS. 2008;22(13):1685-1687.
43. Schmidt SM, Raible A, Kortüm F, et al. Successful treatment of multicentric Castleman's disease with combined immunochemotherapy in an AIDS patient with multiorgan failure. Leukemia. 2008;22(9):1782-1785.
44. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol. 1996;36(1):55-63.
45. de Sanjosé S, Marshall V, Solà J, et al. Prevalence of Kaposi's sarcoma-associated herpesvirus infection in sex workers and women from the general population in Spain. Int J Cancer. 2002;98(1):155-158.
46. Whitby D, Marshall VA, Bagni RK, et al. Reactivation of Kaposi's sarcoma-associated herpesvirus by natural products from Kaposi's sarcoma endemic regions. Int J Cancer. 2007;120(2):321-328.
47. Yuan CC, Miley W, Waters D. A quantification of human cells using an ERV-3 real time PCR assay. J Virol Methods. 2001;91(2):109-117.
48. Krown SE, Metroka C, Wernz JC; AIDS Clinical Trials Group Oncology Committee. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. J Clin Oncol. 1989;7(9):1201-1207.
49. Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol. 1998;16(3):1112-1121.
50. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1983;309(8):453-458.
51. Shiels MS, Landgren O, Costello R, Zingone A, Goedert JJ, Engels EA. Free light chains and the risk of AIDS-defining opportunistic infections in HIV-infected individuals. Clin Infect Dis. 2012; 55(10):e103-e108.
52. Bibas M, Trotta MP, Cozzi-Lepri A, et al; ICONA Foundation Study Group. Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. Am J Hematol. 2012;87(8):749-753.
53. Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol. 2010;28(5):773-779.
54. Stebbing J, Adams C, Sanitt A, et al. Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. Blood. 2011;118(2):271-275.
55. Gasperini P, Sakakibara S, Tosato G. Contribution of viral and cellular cytokines to Kaposi's sarcoma-associated herpesvirus pathogenesis. J Leukoc Biol. 2008;84(4):994-1000.
56. Staskus KA, Sun R, Miller G, et al. Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. J Virol. 1999;73(5):4181-4187.
57. Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood. 2001;97(7):2130-2136.
58. Chadburn A, Hyjek EM, Tam W, et al. Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV-8)-infected B cells in HIV+ multicentric Castleman disease (MCD). Histopathology. 2008;53(5):513-524.
59. Naresh KN, Trivedi P, Horncastle D, Bower M. CD20 expression in the HHV-8-infected lymphoid cells in multicentric Castleman disease. Histopathology. 2009;55(3):358-359.
60. Tosato G, Seamon KB, Goldman ND, et al. Monocyte-derived human B-cell growth factor identified as interferon-beta 2 (BSF-2, IL-6). Science. 1988;239(4839):502-504.
61. Tosato G, Tanner J, Jones KD, Revel M, Pike SE. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol. 1990;64(6):3033-3041.
62. Kehrl JH, Rieckmann P, Kozlow E, Fauci AS. Lymphokine production by B cells from normal and HIV-infected individuals. Ann N Y Acad Sci. 1992;651:220-227.
63. Kitani A, Hara M, Hirose T, et al. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin Exp Immunol. 1992;88(1):75-83.
64. Burdin N, Rousset F, Banchereau J. B-cell-derived IL-10: production and function. Methods. 1997;11(1):98-111.
65. Song J, Ohkura T, Sugimoto M, et al. Human interleukin-6 induces human herpesvirus-8 replication in a body cavity-based lymphoma cell line. J Med Virol. 2002;68(3):404-411.
66. Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115(15):3017-3024.
67. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538-1543.